CDX 1135

Drug Profile

CDX 1135

Alternative Names: BRL 55730; CDX-1135; sCR1; Soluble complement receptor 1; Soluble complement receptor type 1; Soluble CR1; TP 10HD; TP10; YM 203

Latest Information Update: 15 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVANT Immunotherapeutics
  • Developer Celldex Therapeutics Inc
  • Class Anti-ischaemics; Recombinant proteins
  • Mechanism of Action Complement system protein inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reperfusion injury
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Allotransplant rejection; Disseminated intravascular coagulation; Lung transplant rejection; Membranoproliferative glomerulonephritis; Multiple sclerosis; Reperfusion injury; Rheumatoid arthritis; Systemic lupus erythematosus; Xenotransplant rejection

Most Recent Events

  • 16 Dec 2015 Biomarkers information updated
  • 15 Apr 2014 Discontinued - Phase-I for Membranoproliferative glomerulonephritis in USA (IV)
  • 15 Apr 2014 Discontinued - Phase-II for Allotransplant rejection in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top